GI Pancreatic - Metastatic

- **First Line Treatment for Advanced or Metastatic Pancreatic Cancer**
  - IRB# 15304
  - Stand up to Cancer: Study of the Safety, Immunopharmacodynamics and Antitumor Activity of Ibrutinib Combined with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma

- **Second Line Treatment for Advanced or Metastatic Pancreatic Cancer**
  - IRB# 16609
  - AM0010-301: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen

- **Third Line Treatment for Advanced or Metastatic Pancreatic Cancer**
  - IRB# 17094

- **Localized**
  - NeoAdjuvant
    - IRB# 11256
    - OHSU Pancreatic IIT Phase 2 Study of Preoperative Chemotherapy with Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic

- **Metastatic**
  - Adjuvant
    - IRB# 17751
  - First Line Treatment for Advanced or Metastatic Pancreatic Cancer
  - Second Line Treatment for Advanced or Metastatic Pancreatic Cancer
  - Third Line Treatment for Advanced or Metastatic Pancreatic Cancer

- **Key**
  - Open for Enrollment
  - In Development
  - Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

10/18/2017